Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

TAME trial: a multi-arm phase II randomised trial of four novel interventions for malnutrition enteropathy in Zambia and Zimbabwe - a study protocol.

Kelly P, Bell L, Amadi B, Bwakura-Dangarembizi M, VanBuskirk K, Chandwe K, Chipunza M, Ngosa D, Chulu N, Hill S, Murch S, Playford R, Prendergast A.

BMJ Open. 2019 Nov 14;9(11):e027548. doi: 10.1136/bmjopen-2018-027548.

2.

Reviewing co-trimoxazole for HIV-exposed, uninfected infants.

Rabie H, Slogrove A, Bwakura-Dangarembizi M.

Lancet Glob Health. 2019 Dec;7(12):e1599-e1600. doi: 10.1016/S2214-109X(19)30454-1. No abstract available.

3.

Establishing Dosing Recommendations for Efavirenz in HIV/TB-Coinfected Children Younger Than 3 Years.

Bwakura Dangarembizi M, Samson P, Capparelli EV, Moore CB, Jean-Philippe P, Spector SA, Chakhtoura N, Benns A, Zimmer B, Purdue L, Jackson C, Wallis C, Libous JL, Chadwick EG; IMPAACT P1070 Study Team.

J Acquir Immune Defic Syndr. 2019 Aug 1;81(4):473-480. doi: 10.1097/QAI.0000000000002061.

PMID:
31241542
4.

Association of Virologic Failure and Nonnucleoside Reverse Transcriptase Inhibitor Resistance Found in Antiretroviral-Naive Children Infected With Human Immunodeficiency Virus and Given Efavirenz-Based Treatment.

Higa N, Pelz A, Birch D, Beck IA, Sils T, Samson P, Bwakura-Dangarembizi M, Bolton-Moore C, Capparelli E, Chadwick E, Frenkel LM.

J Pediatric Infect Dis Soc. 2019 Jun 13. pii: piz038. doi: 10.1093/jpids/piz038. [Epub ahead of print]

PMID:
31194860
5.

Inflammatory biomarkers in HIV-infected children hospitalized for severe malnutrition in Uganda and Zimbabwe.

Prendergast AJ, Berejena C, Pimundu G, Shonhai A, Bwakura-Dangarembizi M, Musiime V, Szubert AJ, Cook AD, Spyer MJ, Nahirya-Ntege P, Kekitiinwa A, Gibb DM, Klein N, Walker AS.

AIDS. 2019 Jul 15;33(9):1485-1490. doi: 10.1097/QAD.0000000000002231.

PMID:
31008797
6.

Cotrimoxazole reduces systemic inflammation in HIV infection by altering the gut microbiome and immune activation.

Bourke CD, Gough EK, Pimundu G, Shonhai A, Berejena C, Terry L, Baumard L, Choudhry N, Karmali Y, Bwakura-Dangarembizi M, Musiime V, Lutaakome J, Kekitiinwa A, Mutasa K, Szubert AJ, Spyer MJ, Deayton JR, Glass M, Geum HM, Pardieu C, Gibb DM, Klein N, Edens TJ, Walker AS, Manges AR, Prendergast AJ.

Sci Transl Med. 2019 Apr 3;11(486). pii: eaav0537. doi: 10.1126/scitranslmed.aav0537.

7.

Health Outcomes, Pathogenesis and Epidemiology of Severe Acute Malnutrition (HOPE-SAM): rationale and methods of a longitudinal observational study.

Bwakura-Dangarembizi M, Amadi B, Bourke CD, Robertson RC, Mwapenya B, Chandwe K, Kapoma C, Chifunda K, Majo F, Ngosa D, Chakara P, Chulu N, Masimba F, Mapurisa I, Besa E, Mutasa K, Mwakamui S, Runodamoto T, Humphrey JH, Ntozini R, Wells JCK, Manges AR, Swann JR, Walker AS, Nathoo KJ, Kelly P, Prendergast AJ; HOPE-SAM study team.

BMJ Open. 2019 Feb 1;9(1):e023077. doi: 10.1136/bmjopen-2018-023077.

8.

Evaluation of weight-based prescription of antiretroviral therapy in children.

Dakshina S, Olaru ID, Khan P, Raman L, McHugh G, Bwakura-Dangarembizi M, Nathoo K, Munyati S, Mujuru H, Ferrand RA.

HIV Med. 2019 Mar;20(3):248-253. doi: 10.1111/hiv.12702. Epub 2019 Jan 11.

9.

Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial.

Kityo C, Szubert AJ, Siika A, Heyderman R, Bwakura-Dangarembizi M, Lugemwa A, Mwaringa S, Griffiths A, Nkanya I, Kabahenda S, Wachira S, Musoro G, Rajapakse C, Etyang T, Abach J, Spyer MJ, Wavamunno P, Nyondo-Mipando L, Chidziva E, Nathoo K, Klein N, Hakim J, Gibb DM, Walker AS, Pett SL; REALITY trial team.

PLoS Med. 2018 Dec 4;15(12):e1002706. doi: 10.1371/journal.pmed.1002706. eCollection 2018 Dec.

10.

Optimizing Clinical Trial Design to Maximize Evidence Generation in Pediatric HIV.

Ford D, Turner R, Turkova A, Penazzato M, Musiime V, Bwakura-Dangarembizi M, Violari A, Chabala C, Puthanakit T, Sudjaritruk T, Cressey TR, Lallemant M, Gibb DM.

J Acquir Immune Defic Syndr. 2018 Aug 15;78 Suppl 1:S40-S48. doi: 10.1097/QAI.0000000000001748.

11.

Intestinal Integrity Biomarkers in Early Antiretroviral-Treated Perinatally HIV-1-Infected Infants.

Koay WLA, Lindsey JC, Uprety P, Bwakura-Dangarembizi M, Weinberg A, Levin MJ, Persaud D.

J Infect Dis. 2018 Aug 24;218(7):1085-1089. doi: 10.1093/infdis/jiy271.

12.

Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial.

Mallewa J, Szubert AJ, Mugyenyi P, Chidziva E, Thomason MJ, Chepkorir P, Abongomera G, Baleeta K, Etyang A, Warambwa C, Melly B, Mudzingwa S, Kelly C, Agutu C, Wilkes H, Nkomani S, Musiime V, Lugemwa A, Pett SL, Bwakura-Dangarembizi M, Prendergast AJ, Gibb DM, Walker AS, Berkley JA; REALITY trial team.

Lancet HIV. 2018 May;5(5):e231-e240. doi: 10.1016/S2352-3018(18)30038-9. Epub 2018 Apr 10. Erratum in: Lancet HIV. 2018 Jul;5(7):e340.

13.

Late Presentation With HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY Trial.

Siika A, McCabe L, Bwakura-Dangarembizi M, Kityo C, Mallewa J, Berkley J, Maitland K, Griffiths A, Baleeta K, Mudzingwa S, Abach J, Nathoo K, Thomason MJ, Prendergast AJ, Walker AS, Gibb DM; REALITY Trial Team.

Clin Infect Dis. 2018 Mar 4;66(suppl_2):S140-S146. doi: 10.1093/cid/cix1142.

14.

Temporal Improvements in Long-term Outcome in Care Among HIV-infected Children Enrolled in Public Antiretroviral Treatment Care: An Analysis of Outcomes From 2004 to 2012 in Zimbabwe.

Makadzange AT, Dougherty L, Birri R, Kupakuwana G, van Dijk J, Bwakura Dangarembizi M, Mothobi N, Phelps B, Ojikutu B, Ndhlovu CE.

Pediatr Infect Dis J. 2018 Aug;37(8):794-800. doi: 10.1097/INF.0000000000001903.

PMID:
29356763
15.

Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial.

Szubert AJ, Prendergast AJ, Spyer MJ, Musiime V, Musoke P, Bwakura-Dangarembizi M, Nahirya-Ntege P, Thomason MJ, Ndashimye E, Nkanya I, Senfuma O, Mudenge B, Klein N, Gibb DM, Walker AS; ARROW Trial Team.

PLoS Med. 2017 Nov 14;14(11):e1002432. doi: 10.1371/journal.pmed.1002432. eCollection 2017 Nov.

16.

Neuropsychological performance in African children with HIV enrolled in a multisite antiretroviral clinical trial.

Boivin MJ, Barlow-Mosha L, Chernoff MC, Laughton B, Zimmer B, Joyce C, Bwakura-Dangarembizi M, Ratswana M, Abrahams N, Fairlie L, Gous H, Kamthunzi P, McCarthy K, Familiar-Lopez I, Jean-Phillippe P, Coetzee J, Violari A, Cotton MF, Palumbo PE; IMPAACT P1104s Study Team.

AIDS. 2018 Jan 14;32(2):189-204. doi: 10.1097/QAD.0000000000001683. Erratum in: AIDS. 2018 Feb 20;32(4):537.

17.

Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa.

Hakim J, Musiime V, Szubert AJ, Mallewa J, Siika A, Agutu C, Walker S, Pett SL, Bwakura-Dangarembizi M, Lugemwa A, Kaunda S, Karoney M, Musoro G, Kabahenda S, Nathoo K, Maitland K, Griffiths A, Thomason MJ, Kityo C, Mugyenyi P, Prendergast AJ, Walker AS, Gibb DM; REALITY Trial Team.

N Engl J Med. 2017 Jul 20;377(3):233-245. doi: 10.1056/NEJMoa1615822.

18.

CYP2B6 genotype-directed dosing is required for optimal efavirenz exposure in children 3-36 months with HIV infection.

Bolton Moore C, Capparelli EV, Samson P, Bwakura-Dangarembizi M, Jean-Philippe P, Worrell C, Heckman B, Purdue L, Spector SA, Benns A, Borkowsky W, Loftis A, Hawkins E, Wallis C, Chadwick EG; IMPAACT P1070 team.

AIDS. 2017 May 15;31(8):1129-1136. doi: 10.1097/QAD.0000000000001463.

19.

Effect of handrubbing using locally-manufactured alcohol-based handrubs in paediatric wards in Harare, Zimbabwe.

Gudza-Mugabe M, Magwenzi MT, Mujuru HA, Bwakura-Dangarembizi M, Robertson V, Aiken AM.

Antimicrob Resist Infect Control. 2017 Jan 11;6:8. doi: 10.1186/s13756-016-0166-8. eCollection 2017.

20.

Adult Hematology and Clinical Chemistry Laboratory Reference Ranges in a Zimbabwean Population.

Samaneka WP, Mandozana G, Tinago W, Nhando N, Mgodi NM, Bwakura-Dangarembizi MF, Munjoma MW, Gomo ZA, Chirenje ZM, Hakim JG.

PLoS One. 2016 Nov 3;11(11):e0165821. doi: 10.1371/journal.pone.0165821. eCollection 2016.

21.

Reduced bacterial skin infections in HIV-infected African children randomized to long-term cotrimoxazole prophylaxis.

Prendergast AJ, Bwakura-Dangarembizi M, Mugyenyi P, Lutaakome J, Kekitiinwa A, Thomason MJ, Gibb DM, Walker AS; ARROW Trial Team.

AIDS. 2016 Nov 28;30(18):2823-2829.

22.

Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa.

Levin MJ, Lindsey JC, Kaplan SS, Schimana W, Lawrence J, McNeal MM, Bwakura-Dangarembizi M, Ogwu A, Mpabalwani EM, Sato P, Siberry G, Nelson M, Hille D, Weinberg GA, Weinberg A.

AIDS. 2017 Jan 2;31(1):49-59.

23.

Baseline Inflammatory Biomarkers Identify Subgroups of HIV-Infected African Children With Differing Responses to Antiretroviral Therapy.

Prendergast AJ, Szubert AJ, Berejena C, Pimundu G, Pala P, Shonhai A, Musiime V, Bwakura-Dangarembizi M, Poulsom H, Hunter P, Musoke P, Kihembo M, Munderi P, Gibb DM, Spyer M, Walker AS, Klein N; ARROW Trial Team.

J Infect Dis. 2016 Jul 15;214(2):226-36. doi: 10.1093/infdis/jiw148. Epub 2016 May 18.

24.

Cryptococcal Meningitis Presenting as a Complication in HIV-infected Children: A Case Series From Sub-Saharan Africa.

Nyazika TK, Masanganise F, Hagen F, Bwakura-Dangarembizi MF, Ticklay IM, Robertson VJ.

Pediatr Infect Dis J. 2016 Sep;35(9):979-80. doi: 10.1097/INF.0000000000001212.

25.

Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy.

Crook AM, Turkova A, Musiime V, Bwakura-Dangarembizi M, Bakeera-Kitaka S, Nahirya-Ntege P, Thomason M, Mugyenyi P, Musoke P, Kekitiinwa A, Munderi P, Nathoo K, Prendergast AJ, Walker AS, Gibb DM; ARROW Trial Team.

BMC Med. 2016 Mar 23;14:50. doi: 10.1186/s12916-016-0593-7.

26.

Clinical, Virologic, Immunologic Outcomes and Emerging HIV Drug Resistance Patterns in Children and Adolescents in Public ART Care in Zimbabwe.

Makadzange AT, Higgins-Biddle M, Chimukangara B, Birri R, Gordon M, Mahlanza T, McHugh G, van Dijk JH, Bwakura-Dangarembizi M, Ndung'u T, Masimirembwa C, Phelps B, Amzel A, Ojikutu BO, Walker BD, Ndhlovu CE.

PLoS One. 2015 Dec 14;10(12):e0144057. doi: 10.1371/journal.pone.0144057. eCollection 2015.

27.

Rheumatic fever and rheumatic heart disease among children presenting to two referral hospitals in Harare, Zimbabwe.

Gapu P, Bwakura-Dangarembizi M, Kandawasvika G, Kao D, Bannerman C, Hakim J, Matenga JA.

S Afr Med J. 2015 Jun 5;105(5):384-8. doi: 10.7196/samj.7898.

PMID:
26242684
28.

Pubertal development in HIV-infected African children on first-line antiretroviral therapy.

Szubert AJ, Musiime V, Bwakura-Dangarembizi M, Nahirya-Ntege P, Kekitiinwa A, Gibb DM, Nathoo K, Prendergast AJ, Walker AS; ARROW Trial Team.

AIDS. 2015 Mar 13;29(5):609-18. doi: 10.1097/QAD.0000000000000590.

29.

Opportunities for improving the efficiency of paediatric HIV treatment programmes.

Revill PA, Walker S, Mabugu T, Nathoo KJ, Mugyenyi P, Kekitinwa A, Munderi P, Bwakura-Dangarembizi M, Musiime V, Bakeera-Kitaka S, Nahirya-Ntege P, Walker AS, Sculpher MJ, Gibb DM.

AIDS. 2015 Jan 14;29(2):201-10. doi: 10.1097/QAD.0000000000000518.

30.
31.

Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior nevirapine exposure for the prevention of mother-to-child HIV transmission.

Lindsey JC, Hughes MD, Violari A, Eshleman SH, Abrams EJ, Bwakura-Dangarembizi M, Barlow-Mosha L, Kamthunzi P, Sambo PM, Cotton MF, Moultrie H, Khadse S, Schimana W, Bobat R, Zimmer B, Petzold E, Mofenson LM, Jean-Philippe P, Palumbo P; P1060 Study Team.

Pediatr Infect Dis J. 2014 Aug;33(8):846-54. doi: 10.1097/INF.0000000000000337.

32.

Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy.

Bwakura-Dangarembizi M, Musiime V, Szubert AJ, Prendergast AJ, Gomo ZA, Thomason MJ, Musarurwa C, Mugyenyi P, Nahirya P, Kekitiinwa A, Gibb DM, Walker AS, Nathoo K; ARROW Trial Team.

Pediatr Infect Dis J. 2015 Feb;34(2):e23-31. doi: 10.1097/INF.0000000000000491.

33.

Pharmacokinetics of zidovudine dosed twice daily according to World Health Organization weight bands in Ugandan HIV-infected children.

Fillekes Q, Kendall L, Kitaka S, Mugyenyi P, Musoke P, Ndigendawani M, Bwakura-Dangarembizi M, Gibb DM, Burger D, Walker AS; ARROW Trial Team.

Pediatr Infect Dis J. 2014 May;33(5):495-8. doi: 10.1097/INF.0000000000000143.

34.

A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa.

Bwakura-Dangarembizi M, Kendall L, Bakeera-Kitaka S, Nahirya-Ntege P, Keishanyu R, Nathoo K, Spyer MJ, Kekitiinwa A, Lutaakome J, Mhute T, Kasirye P, Munderi P, Musiime V, Gibb DM, Walker AS, Prendergast AJ.

N Engl J Med. 2014 Jan 2;370(1):41-53. doi: 10.1056/NEJMoa1214901. Erratum in: N Engl J Med. 2014 Jan 30;370(5):488. Dosage error in article text.

35.

Ethical and legal constraints to children's participation in research in Zimbabwe: experiences from the multicenter pediatric HIV ARROW trial.

Bwakura-Dangarembizi M, Musesengwa R, Nathoo KJ, Takaidza P, Mhute T, Vhembo T.

BMC Med Ethics. 2012 Jul 20;13:17. doi: 10.1186/1472-6939-13-17.

36.

Pediatric underdosing of efavirenz: a pharmacokinetic study in Uganda.

Fillekes Q, Natukunda E, Balungi J, Kendall L, Bwakura-Dangarembizi M, Keishanyu R, Ferrier A, Lutakome J, Gibb DM, Burger DM, Walker AS; ARROW Trial Team.

J Acquir Immune Defic Syndr. 2011 Dec 1;58(4):392-8. doi: 10.1097/QAI.0b013e318235e560.

PMID:
21926634
37.

Hospitalization for severe malnutrition among HIV-infected children starting antiretroviral therapy.

Prendergast A, Bwakura-Dangarembizi MF, Cook AD, Bakeera-Kitaka S, Natukunda E, Nahirya Ntege P, Nathoo KJ, Karungi C, Lutaakome J, Kekitiinwa A, Gibb DM.

AIDS. 2011 Apr 24;25(7):951-6. doi: 10.1097/QAD.0b013e328345e56b.

PMID:
21487251
38.

Low incidence of abacavir hypersensitivity reaction among African children initiating antiretroviral therapy.

Nahirya-Ntege P, Musiime V, Naidoo B, Bakeera-Kitaka S, Nathoo K, Munderi P, Mugyenyi P, Kekitiinwa A, Bwakura-Dangarembizi MF, Crawley J; ARROW Trial Team.

Pediatr Infect Dis J. 2011 Jun;30(6):535-7. doi: 10.1097/INF.0b013e3182076864.

PMID:
21164384
39.

Antiretroviral treatment for children with peripartum nevirapine exposure.

Palumbo P, Lindsey JC, Hughes MD, Cotton MF, Bobat R, Meyers T, Bwakura-Dangarembizi M, Chi BH, Musoke P, Kamthunzi P, Schimana W, Purdue L, Eshleman SH, Abrams EJ, Millar L, Petzold E, Mofenson LM, Jean-Philippe P, Violari A.

N Engl J Med. 2010 Oct 14;363(16):1510-20. doi: 10.1056/NEJMoa1000931.

Supplemental Content

Loading ...
Support Center